FMPV 1
Alternative Names: FMPV-1Latest Information Update: 28 Jan 2026
At a glance
- Originator Hubro Therapeutics
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer; Gastric cancer
Most Recent Events
- 28 Jan 2026 No recent reports of development identified for preclinical development in Colorectal-cancer(Prevention) in Norway (Intradermal, Injection)
- 28 Jan 2026 No recent reports of development identified for preclinical development in Gastric-cancer in Norway (Intradermal, Injection)
- 28 Jan 2026 No recent reports of development identified for preclinical development in Gastric-cancer(Prevention) in Norway (Intradermal, Injection)